Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges

Wenjian Li

Open source

DOI
10.2147/ijn.s629751
Published
2026-08
Container
International Journal of Nanomedicine
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/ijn.s629751,
  title = {Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges},
  author = {Wenjian Li},
  year = {2026},
  journal = {International Journal of Nanomedicine},
  doi = {10.2147/ijn.s629751},
  url = {https://doi.org/10.2147/ijn.s629751}
}

RIS

TY  - JOUR
TI  - Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges
AU  - Wenjian Li
PY  - 2026
JO  - International Journal of Nanomedicine
DO  - 10.2147/ijn.s629751
UR  - https://doi.org/10.2147/ijn.s629751
ER  - 

APA

Li, W. (2026). Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s629751

Source records